Ironwood is a pharmaceutical company that discovers, develops, and intends to commercialize innovative medicines targeting important therapeutic needs. Ironwood's lead drug candidate Linaclotide, a first-in-class compound for treatment of patients with irritable bowel syndrome with constipation or chronic constipation, is currently in Phase III development.
We have initiated coverage of IRWD at Overweight with a $19 price target. Ironwood has a Phase III drug, linaclotide,
being developed for chronic constipation (CC) and irritable bowel syndrome with constipation (IBS-C). We see a high
chance of clinical and regulatory success as well as blockbuster sales potential for linaclotide, which is likely to be the
first IBS-C drug with a significant pain benefit.
Ironwood Pharmaceuticals Blockbuster Opportunity with Near-Term Catalyst
No comments:
Post a Comment